ZNTL Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 24.82% compared to Zentalis Pharmaceuticals, Inc.'s net margin of -12425.36%. Zentalis Pharmaceuticals, Inc.'s return on equity of -49.3% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Zentalis Pharmaceuticals, Inc. has a consensus price target of $6.19, signalling upside risk potential of 327.39%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Zentalis Pharmaceuticals, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Zentalis Pharmaceuticals, Inc. is more attractive than Perspective Therapeutics, Inc..

Zentalis Pharmaceuticals, Inc. has a beta of 1.752, which suggesting that the stock is 75.241% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Zentalis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentalis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Zentalis Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Zentalis Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Zentalis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentalis Pharmaceuticals, Inc. is 3.63x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of 24.82% compared to Zentalis Pharmaceuticals, Inc.'s net margin of 12.65%. Zentalis Pharmaceuticals, Inc.'s return on equity of -49.3% beat Electromed, Inc.'s return on equity of 18.89%.

Zentalis Pharmaceuticals, Inc. has a consensus price target of $6.19, signalling upside risk potential of 327.39%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 26.32%. Given that Zentalis Pharmaceuticals, Inc. has higher upside potential than Electromed, Inc., analysts believe Zentalis Pharmaceuticals, Inc. is more attractive than Electromed, Inc..

Zentalis Pharmaceuticals, Inc. has a beta of 1.752, which suggesting that the stock is 75.241% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Zentalis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentalis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Zentalis Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Zentalis Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Zentalis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentalis Pharmaceuticals, Inc. is 3.63x versus 3.80x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Glaukos Corp. has a net margin of 24.82% compared to Zentalis Pharmaceuticals, Inc.'s net margin of -12.16%. Zentalis Pharmaceuticals, Inc.'s return on equity of -49.3% beat Glaukos Corp.'s return on equity of -11.73%.

Zentalis Pharmaceuticals, Inc. has a consensus price target of $6.19, signalling upside risk potential of 327.39%. On the other hand Glaukos Corp. has an analysts' consensus of $124.07 which suggests that it could grow by 6.77%. Given that Zentalis Pharmaceuticals, Inc. has higher upside potential than Glaukos Corp., analysts believe Zentalis Pharmaceuticals, Inc. is more attractive than Glaukos Corp..

Zentalis Pharmaceuticals, Inc. has a beta of 1.752, which suggesting that the stock is 75.241% more volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.762%.

Zentalis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentalis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Zentalis Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Glaukos Corp. quarterly revenues of $133.5M. Zentalis Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Glaukos Corp.'s net income of -$16.2M. Notably, Zentalis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentalis Pharmaceuticals, Inc. is 3.63x versus 14.03x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 24.82% compared to Zentalis Pharmaceuticals, Inc.'s net margin of 3.93%. Zentalis Pharmaceuticals, Inc.'s return on equity of -49.3% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Zentalis Pharmaceuticals, Inc. has a consensus price target of $6.19, signalling upside risk potential of 327.39%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Zentalis Pharmaceuticals, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Zentalis Pharmaceuticals, Inc. is more attractive than Xtant Medical Holdings, Inc..

Zentalis Pharmaceuticals, Inc. has a beta of 1.752, which suggesting that the stock is 75.241% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Zentalis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentalis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Zentalis Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Zentalis Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Zentalis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentalis Pharmaceuticals, Inc. is 3.63x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.